Business Wire

EV Growth Closes US$250 Million Fund

Share

EV Growth, a Singapore headquartered venture capital firm, has hit the hard cap of its first fund at US$250 Million, exceeding the firm’s initial US$150 Million target. This milestone is the result of the firm’s admission of new Limited Partners (LPs) which include several Asian based family offices and two of Asia’s largest sovereign wealth funds.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191230005362/en/

EV Growth team. (Photo: Business Wire)

EV Growth team. (Photo: Business Wire)

Launched in March 2018, EV Growth is a joint venture between East Ventures, SMDV and Yahoo! Japan Capital that focuses on providing growth capital to startups in Indonesia and the rest of Southeast Asia with an industry agnostic focus. The company is led by three partners - Willson Cuaca from East Ventures, Roderick Purwana from SMDV, and Shinichiro Hori from Yahoo! Japan Capital.

EV Growth has invested across different sectors in Southeast Asia. Some of its recent investments included:

  • Indonesia leading Edutech Ruangguru US$150 Million Series C round
  • Indonesia leading Beauty-tech Sociolla US$40 Million Series D round
  • Regional cashback startup Shopback US$45 Million round
  • Indonesia supply chain logistic Warung Pintar US$27.5 Million Series B
  • Indonesia trucking and warehousing platform Waresix US$14.5 Million Series A

Other major follow on rounds included the latest round of two Indonesian unicorns Tokopedia and Traveloka, Indonesia SME lending Koinworks, Indonesia premium online-to-offline coffe chain Fore Coffee, and Indonesia leading media company IDN Media.

Presently, EV Growth has deployed more than 50 per cent of its total funds in 20 deals. 80 per cent of EV Growth’s portfolio companies are Indonesian, where the fund’s IRR stands at 36 per cent.

Willson Cuaca, Managing Partner of EV Growth and co-founder of East Ventures said, “The inflection point in Southeast Asia is now and we are lucky to be here early. Our firm’s operating experience, deal velocity, local knowledge and regional networks have helped us capture some of the best deals in the region. We plan to deploy US$325 Million for Southeast Asian startups combining active funds size, for both seed and growth stage.”

By having two funds, East Ventures supports the start-up ecosystem and has been consistent, long term and founder friendly. In example, East Ventures has been a long-time supporter of Ruangguru where Willson Cuaca was a board member since the initial stage and participated in the company’s seed round in 2014. East Ventures assisted with the follow-on round and supported further through EV Growth fund by investing in its recent US$150 Million series C round.

“We are proud to have East Ventures as our partner. Willson Cuaca from EV Growth believed in us from the very beginning and gave us our first seed funding in 2014. We are thankful that EV Growth supported us and participated in our latest US$150 Million round. We continue to demonstrate a strong commitment to East Ventures and look forward to working together with them to reach even greater heights," added Adamas Belva Syah Devara, CEO and co-founder of Ruangguru.

About EV Growth

EV Growth is a joint venture between East Ventures, SMDV, and Yahoo! Japan Capital that is focused on providing growth capital to startups in Indonesia and the rest of Southeast Asia with an agnostic industry focus. EV Growth has one of the largest networks of companies and partners in the region and has invested in more than 20 portfolio companies since its first close in April 2018.

EV Growth aims to bridge the gap in VC growth funding with the ultimate goal of creating a well-diversified portfolio of Southeast Asia early growth tech stage leaders. Leveraging Sinar Mas' deep business knowledge and combined with East Ventures' reputation as one of the leading VCs with the largest seed and Series A portfolios in the region as well as Yahoo! Japan Capital's long experience in the Internet industry, EV Growth has unrivaled access and insight into upcoming trends and opportunities in the industry.

About East Ventures

Founded in 2009, East Ventures is an early-stage sector-agnostic venture capital firm. The firm has supported more than 170 companies in the Southeast Asian region that are present across Indonesia, Singapore, Japan, Malaysia, Thailand, and Vietnam.

An early believer in the startup ecosystem in Indonesia, East Ventures is the first investor of Indonesia's unicorn companies, namely Tokopedia and Traveloka. Other notable companies in the portfolio include Mercari, Warung Pintar, Fore Coffee, Disdus (acquired by Groupon), Kudo (acquired by Grab), Loket (acquired by Gojek), Tech in Asia, Omise, IDN Media, Ruangguru, MokaPOS, ShopBack, and CoHive.

In 2018, to further support and capitalize on the development of their ecosystem, East Ventures set up a growth stage fund named EV Growth. The following year, East Ventures was named the most consistent top performing VC fund globally by Preqin and the most active investor in SEA and Indonesia.

Contact information

Media
Gladys Nathania, Media Relation, East Ventures
Phone: +62 81319301170, email: Gladys@east.vc

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 13:55:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new

Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 13:00:00 EESTPress release

Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95

Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 10:30:00 EESTPress release

Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu

Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 09:00:00 EESTPress release

Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price

ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 08:00:00 EESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel ® (lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatm

Vifor Pharma Group Announces Successful Sale of OM Pharma18.9.2020 08:00:00 EESTPress release

Regulatory News: Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include: A purchase consideration of MCHF 435 for 100% of the share capital An earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple This earn out together with the purchase consideration could result in a total transaction value exceeding MCHF 500. The deal is expected to close within 30 days. OM Pharma is a Geneva-based company mainly active in the field of microbial derived immunotherapeutics and has developed strongly outside the core strategy of Vifor Pharma over the past few years. Optimus Holding Ltd. is a Swiss Group, founded by Etienne Jornod together with long-standing Swiss entrepreneurs and Abdi Ibrahim (28.5%), a Turkey-based pharmaceutical company operating in 12 countries a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom